|Bid||9.65 x 1000|
|Ask||9.66 x 3000|
|Day's range||9.26 - 9.67|
|52-week range||7.99 - 14.10|
|Beta (5Y monthly)||1.43|
|PE ratio (TTM)||15.67|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood's (IRWD) pipeline candidate, IW-3718, fails to meet primary endpoint in a phase III study evaluating it in patients with refractory GERD.
Ironwood expects to incur one-time costs of about $10 million to $12 million in connection with discontinuing trial and planned reduction in workforce. It said it will focus on growth of its constipation drug, Linzess, marketed by AbbVie Inc <ABBV.N>. Linzess is on track to bring in more than $1 billion in sales, Ironwood reiterated on an investor call.